NCT07528066

Downstaging and RATS After Neo-Chemo-IO: Impact on Surgical Outcomes in NSCLC

The Impact of Downstaging on Robotic Surgical Outcomes After Neoadjuvant Chemo-Immunotherapy in Non-Small Cell Lung Cancer

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 200 (estimated)
• Sponsor: Shanghai Chest Hospital · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

The goal of this observational study is to learn whether tumor and nodal downstaging after neoadjuvant chemo-immunotherapy is associated with better surgical outcomes in patients with clinical stage IIB-III non-small cell lung cancer (NSCLC) undergoing robotic-assisted thoracic surgery. The main question it aims to answer is: Is downstaging after neoadjuvant chemo-immunotherapy associated with better surgical outcomes in patients with stage IIB-III NSCLC undergoing robotic-assisted surgery? Participants with resectable or potentially resectable stage IIB-III NSCLC who receive neoadjuvant chemo-immunotherapy as part of their routine clinical care and then undergo curative-intent robotic-assisted surgery will be prospectively enrolled from international centers. Clinical, operative, pathological, and postoperative outcome data will be collected, including R0 resection, the extent of resection, conversion to open surgery, postoperative complications, length of stay, readmission, and mortality.

Detailed description

Please check all details of this study in Clinicaltrials.gov

Conditions

• Neoadjuvant Chemoimmunotherapy
• Robotic Pulmonary Resection
• Stage IIB-III NSCLC

Interventions

Type	Name	Description
PROCEDURE	Robotic-assisted surgery (RATS)	Robotic pulmonary surgery for patients with neoadjuvant chemo-immunotherapy for stage IIB-III non-small cell lung cancer

Timeline

• Start date: 2026-03-02
• Primary completion: 2027-03-30
• Completion: 2027-03-30
• First posted: 2026-04-14
• Last updated: 2026-04-14

Locations

10 sites across 3 countries: China, France, Italy